Top Markets
Coin of the day
Hepion Pharmaceuticals, Inc. Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc.

HEPA
Hisse Senetlerindeki Sıralama #38984
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is... Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
Hisse Fiyatı
$0.0601
Piyasa Değeri
$699.79K
Değişim (1 gün)
-14.14%
Değişim (1 yıl)
0.17%
Ülke
US
Ticaret Hepion Pharmaceuticals, Inc. (HEPA)

Kategori

Hepion Pharmaceuticals, Inc. (HEPA) için kazanç
2026 itibarıyla kazanç TTM: 0
Hepion Pharmaceuticals, Inc. şirketinin en son finansal raporlarına göre, mevcut kazancı 0'dir. 2026 yılında şirket 0 kazanç elde etti, bu 2026 yılındaki 0 kazanca göre önceki yıla eşit. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Hepion Pharmaceuticals, Inc. için kazanç geçmişi 2026 - 2026
Her yılın sonundaki kazanç
Yıl Kazanç Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakipler için kazanç
Şirket Kazanç Kazanç Farkı Ülke
$5.27B -
US
$1.95B -
NL
- -
CH
- -
KR
$3.01B -
BE